According to a Reuters article
, a new drug from Sanofi
effectively cut LDL cholesterol
in late-stage trials. The injectable drug is from a class of medicines called PCSK9 inhibitors, and is called alirocumab
. In Phase III ODYSSEY trials
, the LDL reduction was consistent with previous results, where alirocumab cut levels by 70 percent when combined with statins such as Lipitor
. The inhibitor stops the body from producing a protein that prevents the elimination of LDL from the bloodstream, and after 18 months of treatment, patients were less prone to cardiovascular events than those on placebo.
Read the article published by Reuters.